Education
About Us
Working with TipRanks
Follow Us
Molecular Partners AG (CH:MOLN)
:MOLN
Earnings Data
Report Date
Mar 12, 2026TBA (Confirmed)
Period Ending
2025 (Q4)Consensus EPS Forecast
-0.31Last Year’s EPS
-0.31Same Quarter Last Year
Based on 1 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
Molecular Partners demonstrated significant progress in advancing their pipeline, particularly with the radio DARPin franchise and T cell engager 533, while maintaining a strong financial position. However, the discontinuation of the Novartis collaboration and resulting revenue impact were notable drawbacks.Company Guidance
Successful Execution of 2024 Program Goals
Molecular Partners advanced their radio DARPin franchise with the lead compound DLL3 targeting 712 passing all IND-enabling studies, ready for clinical trials. They selected mesothelin as a new target and expanded their collaboration with Orano Med, securing 10 slots for Lead-212 isotope.
Positive Financial Health
The company ended 2024 with a cash balance of CHF 149 million, which supports operations into 2027. They raised CHF 20 million through financing, maintaining a solid financial base with no debt.
Encouraging Clinical Results and Pipeline Progression
The T cell engager 533 showed significant improvements in efficacy with new dosing strategies, resulting in 3 complete responses out of 8 patients treated past day 12.
CH:MOLN Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CH:MOLN Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 25, 2025 | CHF2.91 | CHF2.93 | +0.69% |
Mar 06, 2025 | CHF4.18 | CHF4.00 | -4.31% |
Aug 26, 2024 | CHF5.49 | CHF5.47 | -0.36% |
Mar 14, 2024 | CHF3.45 | CHF3.50 | +1.45% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Molecular Partners AG (CH:MOLN) report earnings?
Molecular Partners AG (CH:MOLN) is schdueled to report earning on Mar 12, 2026, TBA (Confirmed).
What is Molecular Partners AG (CH:MOLN) earnings time?
Molecular Partners AG (CH:MOLN) earnings time is at Mar 12, 2026, TBA (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is the P/E ratio of Molecular Partners AG stock?
The P/E ratio of Molecular Partners AG is N/A.
What is CH:MOLN EPS forecast?
CH:MOLN EPS forecast for the fiscal quarter 2025 (Q4) is -0.31.